ストックスクリーナーアプリを入手
53.78
0.94%
-0.51
前日終値:
$54.29
開ける：
$54.46
24時間の取引高:
1.63M
Relative Volume:
0.73
時価総額：
$8.96B
収益：
$1.56B
当期純損益:
$152.72M
株価収益率:
59.80
EPS:
0.8994
ネットキャッシュフロー:
$221.80M
1週間 パフォーマンス:
-1.47%
1か月 パフォーマンス:
+21.43%
6か月 パフォーマンス:
+81.32%
1年 パフォーマンス:
+79.39%
1日の値動き範囲:
$53.36
$54.90
1週間の範囲:
$53.36
$55.67
52週間の値動き範囲:
$25.16
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
53.78 | 9.05B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
16.61 | 52.93B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.71 | 42.94B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.10 | 38.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.08 | 31.48B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
552.48 | 23.53B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-06-29 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2025-11-11 | 開始されました | Truist | Buy |
| 2025-09-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Alkermes plc Files 8-K Termination Report: Company Overview, NASDAQ Listing, and Key Details (July 2026) - Minichart
Alkermes plc outlines its role in neuroscience therapies as a global biopharmaceutical company - AD HOC NEWS
Insider Sell: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes stock hits 52-week high at 55.28 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 55.28 USD - Investing.com
Alkermes (ALKS) EVP David Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) notice: David Gaffin lists proposed Common Stock sales in 2026 - Stock Titan
Price to earnings forward of Alkermes plc – NASDAQ:ALKS - TradingView
Granules India secures sole First-to-File status for generic drug - The Times of India
ALKSAlkermes plc Volatility & Greeks - Finviz
(ALKS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion - simplywall.st
ALKS Maintains Rating by Mizuho -- Price Target Raised to $65 - GuruFocus
Mizuho raises Alkermes stock price target to $65 on narcolepsy drug potential - Investing.com
Alkermes (ALKS) R&D chief exercises 5,000 options and sells 9,000 shares - Stock Titan
Alkermes (ALKS) shows multiple 9,000-share insider sales, exercise and vesting - Stock Titan
Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 AdditionWhat's Changed - Yahoo Finance
A Look at Alkermes PLC (ALKS) After 4.8% Decline -- GF Value $31 - GuruFocus
Alkermes plummets on mid-stage Alixorexton data for narcolepsy - MSN
ALKS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
ALKS Downgraded by B of A Securities -- Rating Changed to Underp - GuruFocus
BofA downgrades Alkermes stock rating on valuation concerns By Investing.com - Investing.com Australia
BofA downgrades Alkermes stock rating on valuation concerns - Investing.com
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Enterprise value to EBIT forward of Alkermes plc – NASDAQ:ALKS - TradingView
Press Release: Alkermes to Report First Quarter Financial Results on May 5, 2026 - Moomoo
Price to sales forward of Alkermes plc – NASDAQ:ALKS - TradingView
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda - BioPharma Dive
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI
Alkermes Public Limited Company Actuals & Estimates (NASDAQ:ALKS) - TradingView
ALKS Forecast — Price Target — Prediction for 2027 - TradingView
Alkermes stock hits 52-week high at 51.77 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 51.77 USD - Investing.com
Liquidity Mapping Around (ALKS) Price Events - Stock Traders Daily
Alkermes Jumps 6.9% After Needham Maintains Buy - AlphaStreet
ALKS Maintained by Needham -- Price Target Raised to $61.00 - GuruFocus
Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tel - GuruFocus
ALKS Maintained by TD Cowen -- Price Target Raised to $50 - GuruFocus
Alkermes plc (ALKS) Stock Analysis: Navigating Growth in Biopharmaceuticals with a 4.88% Upside - DirectorsTalk Interviews
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alkermes presents detailed positive results from Vibrance-2 phase 2 study of Alixorexton in adults with narcolepsy type 2 at SLEEP 2026 - MSN
Alkermes announces orphan drug designations for Alixorexton in the US and Europe - MSN
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS) - Seeking Alpha
Did Positive Vibrance-2 Data for Alixorexton Just Shift Alkermes' (ALKS) Investment Narrative? - simplywall.st
Alkermes stock hits 52-week high at 45.76 USD By Investing.com - Investing.com India
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
1.63%
1.30%
大文字化:
|
ボリューム (24 時間):